'Cysteine' Chapel, Holy Grail? Principia Funding Nets $12.5M

Principia Biopharma Inc.'s $12.5 million in new money should get the company's lead compound into human trials, but the company is entertaining the idea of partners to advance other prospects arising from its platform that develops reversible, tightly binding covalent therapies.